G-Magsulph4 gm/100 ml

G-Magsulph (magnesium sulfate, heptahydrate salt form; the heptahydrate crystalline form is also known as Epsom salt) is used for different purposes depending on the route and formulation:

Established / FDA-approved uses (parenteral - IV/IM)

• Prevention and control of seizures in pre-eclampsia and eclampsia - the standard of care in obstetric practice, given intravenously (with intramuscular as an alternative where IV access/monitoring is limited).
• Treatment of hypomagnesemia (low blood magnesium) and correction of magnesium deficiency states.
• Treatment of life-threatening cardiac arrhythmias associated with hypomagnesemia, and torsades de pointes ventricular tachycardia.

Guideline-supported adjunct uses

• Severe acute asthma exacerbations refractory to initial bronchodilator/corticosteroid therapy, used as an adjunct (add-on) to standard asthma treatment, not as monotherapy.
• Preterm labor - fetal neuroprotection, given short-term to women at risk of very preterm delivery to reduce the risk of cerebral palsy in the infant (per obstetric guidelines).

Oral / rectal use

• Short-term relief of occasional constipation (saline laxative effect) and, in some regimens, bowel evacuation before certain procedures.

Topical use

• Soothing soak for minor muscle aches or minor skin irritation (topical/bath use), a non-prescription, low-evidence traditional use.

The intravenous/obstetric-emergency use of G-Magsulph is a distinct clinical context, with different dosing and monitoring requirements, from its oral laxative or topical soak use - these should never be confused.

Each formulation of Magnesium Sulfate Heptahydrate contains magnesium sulfate as the heptahydrate salt (MgSO4·7H2O), which provides elemental magnesium and sulfate ions. It is available as:

• Sterile injectable solution for intravenous (IV) or intramuscular (IM) use, in various concentrations (e.g., 2.5 g/5 mL, 4 g/100 mL as marketed locally).
• Oral powder/crystals (for reconstitution as an oral solution) used as a laxative.

No fixed-dose combination form is standard; Magnesium Sulfate Heptahydrate is generally administered as a single-ingredient product with the diluent/vehicle appropriate to the route (e.g., water for injection, dextrose solution for IV infusion).

G-Magsulph is an inorganic salt of magnesium, essential for numerous enzymatic reactions, neuromuscular transmission, and cardiac electrical stability. The heptahydrate crystal form (commonly known as Epsom salt) is highly water-soluble.

Clinically, G-Magsulph acts as an anticonvulsant in obstetric practice, an electrolyte replacement product, an antiarrhythmic in specific settings, a bronchodilator adjunct in severe asthma, and (via the oral/rectal route) an osmotic (saline) laxative.

G-Magsulph belongs to the class of electrolyte replenishers / anticonvulsants (obstetric) and, in oral/rectal form, saline (osmotic) laxatives. It is also classified as a class of antiarrhythmic agents in specific indications such as torsades de pointes.

Magnesium is the second most abundant intracellular cation and a cofactor for over 300 enzymatic reactions, including those involved in protein synthesis, muscle and nerve function, and cardiac excitability.

As an anticonvulsant in eclampsia, Magnesium Sulfate Heptahydrate is believed to act at the neuromuscular junction and centrally by blocking NMDA-receptor-mediated calcium influx and reducing acetylcholine release, which raises the seizure threshold and produces mild central nervous system depression, and also causes cerebral and peripheral vasodilation.

As an antiarrhythmic, magnesium stabilizes cardiac cell membranes and is particularly effective for torsades de pointes and digoxin-induced arrhythmias.

In severe asthma, magnesium relaxes bronchial smooth muscle via calcium-channel-blocking activity at the smooth-muscle cell membrane.

Given orally, unabsorbed magnesium sulfate exerts an osmotic effect in the intestinal lumen, drawing water into the bowel and stimulating peristalsis.

Magnesium is excreted almost entirely by the kidneys, so renal function directly determines the risk of magnesium accumulation and toxicity.

G-Magsulph for injection must be administered by, or under the direct supervision of, a qualified healthcare professional in a setting where cardiac/respiratory monitoring and calcium gluconate (the antidote) are readily available. IV infusions are typically diluted and given via an infusion pump to control the rate precisely. IM injections are given deep into a large muscle.

Oral doses for constipation should be dissolved completely in a full glass of water and taken with additional fluids as advised.

G-Magsulph has the following well-documented, clinically significant interactions:

• CNS depressants (opioids, barbiturates, general anesthetics): additive CNS and respiratory depression when combined with parenteral G-Magsulph.
• Neuromuscular blocking agents: magnesium potentiates the effect of both depolarizing and non-depolarizing neuromuscular blockers, increasing the risk of prolonged or profound muscle paralysis and respiratory depression.
• Calcium channel blockers (e.g., nifedipine): concurrent use with IV G-Magsulph may cause additive hypotension and neuromuscular blockade.
• Digoxin: caution is advised, as significant changes in magnesium levels can precipitate cardiac conduction disturbances in digitalized patients.
• Aminoglycoside antibiotics: may have additive neuromuscular blocking effects with parenteral magnesium, increasing the risk of respiratory depression.
• Oral drugs, in general (with oral/laxative use): magnesium sulfate taken orally may reduce the absorption of certain oral medications (e.g., tetracyclines, some fluoroquinolones) by chelation; separate dosing by at least 2 hours.

Side effects of G-Magsulph depend on the route and dose:

Parenteral (IV/IM) use

• Common: flushing, sensation of warmth, sweating, hypotension (due to vasodilation), nausea, vomiting, drowsiness, headache.
• Signs of rising magnesium levels (dose-related): loss of deep tendon reflexes, muscle weakness, slurred speech, blurred vision.
• Serious (with magnesium toxicity): respiratory depression/paralysis, cardiac conduction abnormalities, cardiac arrest - these are the reason for close monitoring during IV/IM use (see Precautions and Warnings).

Oral/rectal use

• Abdominal cramping, diarrhea, bloating, nausea.

Topical use

• Skin irritation (uncommon).

G-Magsulph is actively used in pregnancy for the specific, guideline-supported indications of pre-eclampsia/eclampsia seizure prevention and fetal neuroprotection in anticipated very preterm birth, under close medical supervision, because in these situations the benefit is considered to outweigh the risk. Magnesium crosses the placenta, and prolonged use (generally beyond 5-7 days) has been associated with fetal/neonatal bone and mineral abnormalities in rare cases, so use for other indications during pregnancy should occur only if clearly needed, with the potential benefit judged to justify the potential risk to the fetus - consult a physician.

Magnesium is excreted into breast milk in small amounts; effects on the nursing infant are not expected to be significant with typical clinical use, but a physician should be consulted before use during breastfeeding, particularly for non-obstetric indications.

G-Magsulph given intravenously or intramuscularly requires close clinical monitoring, including deep tendon reflexes, respiratory rate, urine output, and serum magnesium concentration, because the therapeutic and toxic doses are relatively close together. Calcium gluconate should be readily available as the specific antidote for magnesium toxicity (e.g., respiratory depression, loss of reflexes, cardiac conduction abnormalities).

Use with caution in patients with any degree of renal impairment even outside the setting of severe renal failure, as magnesium is renally excreted and toxicity risk rises with reduced kidney function - this applies to oral/rectal use as well, not only parenteral use.

Oral/rectal use as a laxative is intended for short-term, occasional use only; regular or prolonged use should be avoided, particularly in the elderly, in patients with renal impairment, and in those with bowel obstruction or acute abdominal conditions (appendicitis, undiagnosed abdominal pain), in whom laxatives should not be used.

Use with caution in myasthenia gravis, as magnesium can worsen neuromuscular weakness.

Overdose of G-Magsulph (magnesium toxicity) can cause progressive loss of deep tendon reflexes, severe muscle weakness, difficulty breathing, dangerously low blood pressure, slowed or irregular heartbeat, and, in severe cases, respiratory paralysis and cardiac arrest.

Suspected overdose is a medical emergency - seek immediate medical attention or contact emergency services/poison control right away. Do not attempt to manage a suspected overdose at home; specific treatment (which may include intravenous calcium gluconate, respiratory support, and discontinuation of magnesium) must be given by trained medical personnel in a monitored setting.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Injectable solutions should be inspected visually for particulate matter or discoloration before use, and any unused portion of a single-use vial/ampoule should be discarded.

Pediatric use: G-Magsulph is used in children under specialist supervision for hypomagnesemia and as an adjunct in severe acute asthma, with weight-based dosing; safety and efficacy for other adult indications have not been formally established in children, and pediatric dosing should always be individualized by a physician.

Elderly: use with caution, as age-related decline in renal function increases the risk of magnesium accumulation; dose adjustment and closer monitoring are advised, especially for oral/laxative use, which should generally be avoided for regular use in this group.

Renal impairment: reduced doses and increased monitoring of serum magnesium are required in any degree of renal impairment; severe renal impairment is a contraindication to parenteral use (see Contraindications).

Hepatic impairment: no specific dose adjustment is established, as magnesium is primarily renally, not hepatically, eliminated.

Duration of G-Magsulph therapy is indication-specific: in pre-eclampsia/eclampsia, IV infusion is typically continued for 24 hours after delivery or after the last seizure; in fetal neuroprotection, a short course is given before anticipated very preterm delivery; in arrhythmia or severe asthma, treatment is typically a single dose or brief infusion; in hypomagnesemia, treatment continues until levels normalize, guided by repeat laboratory testing. Oral/rectal laxative use should be limited to short-term, occasional use (generally no more than a few days) unless otherwise directed by a physician.

Certain concentrated injectable presentations of G-Magsulph (e.g., ampoules of concentrated magnesium sulfate solution intended for IV infusion) must be diluted in a compatible IV fluid (such as 5% dextrose or normal saline) to the required concentration before intravenous infusion, per the product labeling and institutional protocol; ready-to-use pre-diluted infusion bags do not require further reconstitution.

Electrolyte / mineral replacement agent; obstetric anticonvulsant; antiarrhythmic (for torsades de pointes); saline (osmotic) laxative (oral/rectal use).

Magnesium Sulfate Heptahydrate provides magnesium ions that act as a physiological calcium antagonist at multiple sites: at the neuromuscular junction it decreases acetylcholine release and reduces motor endplate sensitivity, raising the seizure threshold; in vascular and bronchial smooth muscle it competes with calcium to promote relaxation and vasodilation/bronchodilation; and in cardiac tissue it stabilizes the cell membrane and slows conduction, which underlies its antiarrhythmic effect. When taken orally and poorly absorbed, magnesium sulfate draws water osmotically into the bowel lumen, producing a laxative effect.

G-Magsulph is used in pediatric patients for treatment of documented hypomagnesemia and, in specialist/emergency settings, as an adjunct in severe acute asthma exacerbations unresponsive to initial bronchodilator therapy, using weight-based dosing under close monitoring. Safety and efficacy for other adult indications (e.g., routine obstetric use, which is not applicable to children) have not been established in pediatric patients. Oral use as a laxative in children should only be done under medical guidance regarding appropriate dose by age/weight.